Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts.

Han D, Rodriguez-Bravo V, Izadmehr S, Domingo-Domenech J, Cordon-Cardo C.

J Vis Exp. 2019 Jun 13;(148). doi: 10.3791/57011.

PMID:
31259909
2.

MIFEPRISTONE TREATMENT FOR MILD AUTONOMOUS CORTISOL SECRETION DUE TO ADRENAL ADENOMAS: A PILOT STUDY.

Belokovskaya R, Ravikumar A, Arumugam D, Izadmehr S, Goddard GM, Geer EB, Levine AC.

Endocr Pract. 2019 May 9. doi: 10.4158/EP-2019-0047. [Epub ahead of print]

PMID:
31070948
3.

Mechanisms of Osteoblastic Bone Metastasis in Prostate Cancer: Role of Prostatic Acid Phosphatase.

Quiroz-Munoz M, Izadmehr S, Arumugam D, Wong B, Kirschenbaum A, Levine AC.

J Endocr Soc. 2019 Feb 1;3(3):655-664. doi: 10.1210/js.2018-00425. eCollection 2019 Mar 1. Review.

4.

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.

Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, Vasireddi N, Dhawan NS, Ma'ayan A, Sharma N, Galsky MD, Ohlmeyer M, Sangodkar J, Narla G.

JCI Insight. 2019 Feb 21;4(4). pii: 125693. doi: 10.1172/jci.insight.125693. eCollection 2019 Feb 21.

5.

Sequential trafficking of Env and Gag to HIV-1 T cell virological synapses revealed by live imaging.

Wang L, Izadmehr S, Kamau E, Kong XP, Chen BK.

Retrovirology. 2019 Jan 15;16(1):2. doi: 10.1186/s12977-019-0464-3.

6.

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. doi: 10.1126/scitranslmed.aaq1093.

PMID:
30021885
7.

Factor XII and uPAR upregulate neutrophil functions to influence wound healing.

Stavrou EX, Fang C, Bane KL, Long AT, Naudin C, Kucukal E, Gandhi A, Brett-Morris A, Mumaw MM, Izadmehr S, Merkulova A, Reynolds CC, Alhalabi O, Nayak L, Yu WM, Qu CK, Meyerson HJ, Dubyak GR, Gurkan UA, Nieman MT, Sen Gupta A, Renné T, Schmaier AH.

J Clin Invest. 2018 Mar 1;128(3):944-959. doi: 10.1172/JCI92880. Epub 2018 Jan 29.

8.

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.

9.

FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.

Liu T, Zhang H, Sun L, Zhao D, Liu P, Yan M, Zaidi N, Izadmehr S, Gupta A, Abu-Amer W, Luo M, Yang J, Ou X, Wang Y, Bai X, Wang Y, New MI, Zaidi M, Yuen T, Liu C.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7683-7688. doi: 10.1073/pnas.1621486114. Epub 2017 Jul 3.

10.

Blocking FSH induces thermogenic adipose tissue and reduces body fat.

Liu P, Ji Y, Yuen T, Rendina-Ruedy E, DeMambro VE, Dhawan S, Abu-Amer W, Izadmehr S, Zhou B, Shin AC, Latif R, Thangeswaran P, Gupta A, Li J, Shnayder V, Robinson ST, Yu YE, Zhang X, Yang F, Lu P, Zhou Y, Zhu LL, Oberlin DJ, Davies TF, Reagan MR, Brown A, Kumar TR, Epstein S, Iqbal J, Avadhani NG, New MI, Molina H, van Klinken JB, Guo EX, Buettner C, Haider S, Bian Z, Sun L, Rosen CJ, Zaidi M.

Nature. 2017 Jun 1;546(7656):107-112. doi: 10.1038/nature22342. Epub 2017 May 24.

11.

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G.

J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15.

12.

Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases.

Kirschenbaum A, Izadmehr S, Yao S, O'Connor-Chapman KL, Huang A, Gregoriades EM, Yakar S, Levine AC.

Endocrinology. 2016 Dec;157(12):4526-4533. Epub 2016 Oct 26.

13.

Erratum to: Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer.

Izadmehr S, Leapman M, Hobbs AR, Katsigeorgis M, Nabizada-Pace F, Jazayeri SB, Samadi DB.

Int Urol Nephrol. 2016 Oct;48(10):1647. No abstract available.

PMID:
27562410
14.

Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer.

Izadmehr S, Leapman M, Hobbs AR, Katsigeorgis M, Nabizada-Pace F, Jazayeri SB, Samadi DB.

Int Urol Nephrol. 2016 Oct;48(10):1639-45. doi: 10.1007/s11255-016-1338-4. Epub 2016 Jun 18. Erratum in: Int Urol Nephrol. 2016 Oct;48(10):1647.

PMID:
27318820
15.

Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].

Kastrinsky DB, Sangodkar J, Zaware N, McClinch K, Farrington CC, Giannini HM, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M.

Bioorg Med Chem. 2015 Dec 1;23(23):7487. doi: 10.1016/j.bmc.2015.11.002. Epub 2015 Nov 9. No abstract available.

PMID:
28290285
16.

Reengineered tricyclic anti-cancer agents.

Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M.

Bioorg Med Chem. 2015 Oct 1;23(19):6528-34. doi: 10.1016/j.bmc.2015.07.007. Epub 2015 Sep 11.

PMID:
26372073
17.

Bisphosphonates inactivate human EGFRs to exert antitumor actions.

Yuen T, Stachnik A, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Bailey J, Latif Y, Mujtaba S, Epstein S, Davies TF, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17989-94. doi: 10.1073/pnas.1421410111. Epub 2014 Dec 1.

18.

Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.

Stachnik A, Yuen T, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Scherer T, Mujtaba S, Galsky M, Gomez J, Epstein S, Buettner C, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17995-8000. doi: 10.1073/pnas.1421422111. Epub 2014 Dec 1.

19.

Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance.

Serasinghe MN, Missert DJ, Asciolla JJ, Podgrabinska S, Wieder SY, Izadmehr S, Belbin G, Skobe M, Chipuk JE.

Oncogene. 2015 Feb 12;34(7):857-67. doi: 10.1038/onc.2014.21. Epub 2014 Mar 10.

20.

Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.

Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG.

Cancer Res. 2014 Feb 15;74(4):1067-78. doi: 10.1158/0008-5472.CAN-13-0588. Epub 2014 Jan 7.

21.

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.

Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, Narla G.

Sci Transl Med. 2013 Jan 23;5(169):169ra12. doi: 10.1126/scitranslmed.3004688.

22.

Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens.

Anvekar RA, Asciolla JJ, Lopez-Rivera E, Floros KV, Izadmehr S, Elkholi R, Belbin G, Sikora AG, Chipuk JE.

Cell Death Dis. 2012 Nov 15;3:e420. doi: 10.1038/cddis.2012.161.

23.

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.

Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, Difeo A, Narla G.

J Clin Invest. 2012 Jul;122(7):2637-51. doi: 10.1172/JCI62058. Epub 2012 Jun 1.

Supplemental Content

Loading ...
Support Center